Renovorx, Inc. earnings releases RNXT

Annual Quarterly

Renovorx, Inc. last reported quarterly results on May 14, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): revenue of $563,000 (+185.8% year over year) and diluted EPS of -$0.09. It usually reports 1–45 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 1–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
May 14, 2026 44 days after quarter end	Q1 FY2026 ended Mar 31, 2026	1 +185.8%	-4 -45.5%	-0.09 -12.5%
Nov 13, 2025 44 days after quarter end	Q3 FY2025 ended Sep 30, 2025	0	-3 -17.8%	-0.08 +20.0%
Aug 14, 2025 45 days after quarter end	Q2 FY2025 ended Jun 30, 2025	0	-3 -21.2%	-0.08 +20.0%
Apr 1, 2025 1 days after quarter end	Q1 FY2025 ended Mar 31, 2025	0	-2 -124.9%	-0.08 -14.3%
Nov 14, 2024 45 days after quarter end	Q3 FY2024 ended Sep 30, 2024	—	-2 -73.9%	-0.10 +23.1%
Nov 14, 2023 45 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 17, 2023 48 days after quarter end	— ended Jun 30, 2023	—	—	—
May 15, 2023 45 days after quarter end	— ended Mar 31, 2023	—	—	—

Company profile

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as: RNXT (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Mountain View, CA
SEC filer status: , Emerging growth company
SEC CIK: 1574094

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.